✦ LIBER ✦

215 Dacarbazine-vindesine vs dacarbazine-vindesine-cisplatinum in disseminated melanoma—a randomized phase III trial

✍ Scribed by U. Jungnelius; U. Ringborg; S. Aamdahl; C.-M. Rudenstam; U. Stierner; C. Ingvar; P. Malmström; R. Andersson; M. Karlsson; K. Willman; E. Wist; R. Westberg

Book ID: 116166974
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 155 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)95472-i

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dacarbazine–vindesine versus dacarbazine

Dacarbazine–vindesine versus dacarbazine–vindesine–cisplatin in disseminated malignant melanoma. A randomised phase III trial

✍ U Jungnelius; U Ringborg; S Aamdal; J Mattsson; U Stierner; C Ingvar; P Malmströ 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Dacarbazine versus dacarbazine-vindesine

Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: A randomized phase II study

✍ U. Ringborg; C. -M. Rudenstam; J. Hansson; L. Hafström; B. Stenstam; H. Strander 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 374 KB

A phase III randomized trial of dacarbaz

A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

✍ Sanjiv S. Agarwala; William Ferri; William Gooding; John M. Kirkwood 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## BACKGROUND. Metastatic melanoma is a disease associated with a poor prognosis, and dacarbazine is still the reference agent. The authors conducted a randomized trial to test the benefit of adding tamoxifen to dacarbazine and carboplatin chemotherapy for previously untreated patients with metast

Lonidamine (LND) vs mitomycin/vindesine

Lonidamine (LND) vs mitomycin/vindesine (MV) vs MV + LND in extensive stage non-small-cell lung cancer (NSCLC) — A prospective randomized phase III-Trial

✍ Gatzemeier, U.; Neuhauss, R.; Koschel, G.; Kaukel, K.; Häussinger, H.; Pawel, J. 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 113 KB

9318 POSTER Phase 3 Randomized Study of

9318 POSTER Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma

✍ Robert, C.; Thomas, L.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Maio, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Mature results of a phase III randomized

Mature results of a phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673) : A trial of the Eastern Cooperative Oncology Group

✍ Sanjiv S. Agarwala; Donna Neuberg; Yuhyun Park; John M. Kirkwood 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

## Abstract ## BACKGROUND The local and systemic effects of bacillus Calmette–Guerin (BCG) have been known for decades. To investigate the adjuvant effect of BCG on resected American Joint Committee on Cancer (AJCC) Stage I–III melanoma, the Eastern Cooperative Oncology Group conducted a large tri